Use of GSK3 inhibitors in combination with radiation therapies
AssigneeVanderbilt University
InventorDennis E. Hallahan
Life of this patent
Estimating the term…
Abstract
The presently disclosed subject matter relates generally to the fields of molecular biology and medicine. More particularly, it concerns methods involving the use of GSK3 inhibitors in combination with radiation therapies. In some embodiments, administration of a GSK3 inhibitor to a subject results in an amelioration of cognitive decline, toxicity to vascular endothelial cells, and/or neuron death associated with radiation therapy alone.
Claims35
A method for treating a hyperproliferative disease in a subject comprising administering radiation therapy in combination with a pharmaceutical composition comprising an inhibitor of glycogen synthase kinase 3 (GSK3) comprising lithium or a pharmaceutically acceptable salt thereof to the subject, wherein the inhibitor of GSK3 is administered to the subject prior to and during administration of the radiation therapy, and in an amount and via a route effective to protect a cell selected from the group consisting of a neuron, a vascular endothelial cell, a salivary gland cell, a gastrointestinal tract cell, a lung cell, and a liver cell from radiation-induced apoptosis.
Dependencies are inferred from the claim text.